Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

ck,

non-fatal stroke or cardiovascular death (p<0.001).

-- 52 percent reduction compared with clopidogrel in stent thrombosis

(p<0.0001).

-- 30 percent relative risk reduction compared to clopidogrel in a subset

of patients with diabetes (p<0.001) on the composite endpoint of non-

fatal heart attack, non-fatal stroke, or cardiovascular death.

Risk reductions in the primary composite endpoint with prasugrel compared to clopidogrel were seen as early as three days and continued to diverge for 15 months (the duration of the trial.)

Though the incidence of non-coronary artery bypass grafting(non-CABG) bleeding in TRITON was low in both the prasugrel and clopidogrel treatment groups, prasugrel-treated patients experienced significantly higher non-CABG major bleeding (2.2% vs. 1.7%, respectively) and higher rates of life- threatening bleeding (1.3% vs. 0.8%, respectively). Death from cardiovascular causes (2% vs. 2.2%, respectively) and all-cause death (2.8% vs. 2.9%, respectively) was comparable among prasugrel-treated patients and clopidogrel- treated patients. The overall results demonstrated that for every 1,000 patients treated with prasugrel as compared with clopidogrel, there were 22 fewer patients with heart attacks and five more non-CABG-related TIMI major bleeds.

"Given the overall results from TRITON, this submission is particularly meaningful considering that cardiovascular disease is the leading cause of death in the United States and worldwide, killing 16.7 million people each year," said John Alexander, M.D., M.P.H., global head of research and development, Daiichi Sankyo Company, Limited.

Acute heart attacks and unstable angina, called acute coronary syndrome, affect more than 840,000 Americans each year and 800,000 people in Europe.(i,ii) Utilizing current medical interventions and treatments, 300,000 people continue to experience recurrent heart attacks and 450,000 people die fro
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/27/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a biopharmaceutical ... innovative therapeutics addressing cancer and other unmet medical needs ... China , today reported financial results ... 2014.  The Company reported a net ... the three months ended December 31, 2014.  This compares ...
(Date:3/26/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... solutions for the detection of foodborne pathogens, today ... and full year ended December 31, 2014. ... quarter ended December 31, 2014 was $1.4 million ... 2013 and $1.5 million for the third quarter ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... NEW BRUNSWICK, N.J., Dec. 5 Senesco Technologies, Inc. ... today that its Development and License Agreement with the ... mutual agreement because of Harris Moran,s recently announced corporate ... Harris Moran has reported that its parent company, Limagrain, ...
... BioCryst Pharmaceuticals (Nasdaq: BCRX ) announced today ... and BCX-4208, and clinical data on BCX-4208 at the 50th ... held in San Francisco, CA from December 6-9, 2008. ... inhibitors. , , The schedule ...
... YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, ... and commercializes differentiated products for patients worldwide, ... licensee of nimotuzumab from YM,s subsidiary, CIMYM ... the European Medicines Agency (EMEA) for marketing ...
Cached Biology Technology:Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 2Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring 3BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 2BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition 3YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 2YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE 3
(Date:3/11/2015)... 11, 2015 Research and Markets ( ... "Access Control Market by Product, Application & By Geography ... to their offering. , This report predicts ... $10.4 billion by 2020, with an estimated CAGR of ... the products types such as contact cards & readers, ...
(Date:3/10/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce ... been named the "Number One Best Tech Gift ... Modern ( http://www.rethinkmodern.com/ ) is a web magazine focused ... that have a unique function or design.  ...
(Date:3/2/2015)... 2015  Businesses have a new option for ... Rankins Enterprises has announced the launch of a ... for businesses to protect their customers, personal data, ... Beconux is a biometric transaction processing system ... to an ATM machine, the new system fuses ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Personal Data Protection Company Launches New Product 2
... of California, Berkeley, virologist and an assistant professor in the ... M. Keck Foundation grant, an award given to innovative young ... which totals up to $1 million over five years, will ... herpesvirus as a tool to study the inner workings of ...
... WORCESTER, Mass.In recent years, a class of small molecules known ... in regulating gene products in most animal and plant species. ... development of alcohol tolerance, a hallmark of alcohol abuse and ... and Alcoholism (NIAAA) report the findings in the July 31 ...
... death but now a study of brain tissue collected during ... and suicide. The international research group, led by Dr. ... of Western Ontario and Dr. Hymie Anisman of the Neuroscience ... that proteins that modify DNA directly are more highly expressed ...
Cached Biology News:UC Berkeley virologist named Keck Distinguished Young Scholar 2MicroRNA implicated as molecular factor in alcohol tolerance 2Study identifies changes to DNA in major depression and suicide 2
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
Biology Products: